Market revenue in 2020 | USD 2,555.8 million |
Market revenue in 2028 | USD 4,077.5 million |
Growth rate | 6% (CAGR from 2020 to 2028) |
Largest segment | Laboratory technologies |
Fastest growing segment | Online Technologies |
Historical data | 2020 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Laboratory Technologies, Online Technologies |
Key market players worldwide | Thermo Fisher Scientific Inc, Pfizer Inc, Sartorius AG, Stemcell Holdings Inc Ordinary Shares, Illumina Inc, Agilent Technologies Inc, Bio-Rad Laboratories Inc, Danaher Corp, Merck KGaA, Qiagen NV, Shimadzu Corp, Eurofins Scientific SE, Charles River Laboratories International Inc, Takara Bio Inc, Olympus Corp, Avantor Inc, Aurora Innovation Inc Class A, Standard BioTools Inc, Celerion, Cole-Parmer, Hartford Schroders International Stk I, Revvity Inc, Fluidigm Corporation, Polyplus-transfection, Hamilton Lane Inc Class A |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to covid-19 vaccine development tools market will help companies and investors design strategic landscapes.
Laboratory technologies was the largest segment with a revenue share of 95.46% in 2020. Horizon Databook has segmented the China covid-19 vaccine development tools market based on laboratory technologies, online technologies covering the revenue growth of each sub-segment from 2020 to 2028.
China is anticipated to be the largest market for COVID-19 vaccine development tools and in 2021, it was valued at USD 2,555.79 million. Various initiatives are being undertaken by domestic companies to develop and commercialize COVID-19 vaccine, which is expected to drive the market growth.
However, high government intervention in development of the COVID-19 vaccine and absence of independent regulatory institutions restrained growth rate in the country. For instance, China denied the use of most effective and popular vaccine technology, mRNA, and employed traditional, inactivated vaccines to accomplish its 86.6% fully vaccinated rate.
However, as per healthcare professionals in the region, inactivated vaccines are ineffective against the new variants. In January 2022, Walvax Biotech, a Chinese pharmaceutical company, published the clinical data of Phase 1 on China’s first in-house mRNA-based vaccine and proved its effectiveness in inducing an immune response.
Horizon Databook provides a detailed overview of country-level data and insights on the China covid-19 vaccine development tools market , including forecasts for subscribers. This country databook contains high-level insights into China covid-19 vaccine development tools market from 2020 to 2028, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account